Latest On MediWound Ltd (MDWD):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-31 22:31 EST | News | MediWound: With Expenses Covered, Growth Is Within Reach | N/A |  |
| 2023-05-30 17:26 EST | News | MediWound GAAP EPS of -$0.44 misses by $0.26, revenue of $3.8M misses by $1.35M | N/A | |
| 2023-05-30 17:26 EST | News | MediWound Ltd. (MDWD) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-30 17:26 EST | News | MediWound slips after Q1 miss | N/A | |
| 2023-05-27 03:57 EST | News | MediWound Q1 Earnings Preview | N/A | |
| 2023-03-16 20:36 EST | News | MediWound names industry veteran as CFO | N/A | |
| 2023-03-16 20:36 EST | News | MediWoundEPS of -$1.18, revenue of $11.62M beats by $5.02M | N/A | |
| 2023-03-16 20:36 EST | News | MediWound Ltd. (MDWD) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-15 13:53 EST | News | MediWound Q4 2022 Earnings Preview | N/A | |
| 2023-01-04 21:36 EST | News | MediWound: Gaining Traction | N/A | |
| 2022-12-29 20:29 EST | News | MediWound, Vericel gain on FDA approval of burn therapy | N/A | |
| 2022-12-23 10:45 EST | News | MediWound's burn treatment Nexobrid approved in Japan | N/A | |
| 2022-12-20 15:02 EST | News | MediWound gets Swiss marketing approval for burns treatment NexoBrid | N/A | |
| 2022-12-06 04:24 EST | News | MediWound announces 1-for-7 reverse share split | N/A | |
| 2022-11-15 21:57 EST | News | MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $5.8M beats by $1.2M | N/A | |
| 2022-11-15 21:57 EST | News | MediWound Ltd. (MDWD) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-15 04:52 EST | News | MediWound Q3 2022 Earnings Preview | N/A | |
| 2022-09-22 20:26 EST | News | MediWound stock slips on ~$30.5M securities offerings | N/A | |
| 2022-09-20 19:14 EST | News | MediWound's NexoBrid for thermal burns in children gets EMA review | N/A | |
| 2022-08-10 02:57 EST | News | MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M | N/A | |
| 2022-08-10 02:57 EST | News | MediWound Ltd. (MDWD) CEO Ofer Gonen on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-10 02:57 EST | News | MediWound Ltd. 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-08-09 05:06 EST | News | MediWound Q2 Earnings Preview | N/A | |
| 2022-08-03 23:17 EST | News | MediWound refiling for NexoBrid to treat severe thermal burns gets FDA review | N/A | |
| 2022-07-07 15:49 EST | News | MediWound adds 13% after favorable data for ulcer candidate | N/A | |
| 2022-06-30 13:41 EST | News | MediWound taps Tzvi Palash as COO | N/A | |
| 2022-05-17 12:25 EST | News | MediWound GAAP EPS of -$0.12 misses by $0.01, revenue of $4.4M beats by $0.11M | N/A | |
| 2022-05-17 12:25 EST | News | MediWound picks industry veteran for CEO role | N/A | |
| 2022-05-17 12:25 EST | News | MediWound Ltd. (MDWD) CEO Sharon Malka on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-16 15:11 EST | News | MediWound Q1 2022 Earnings Preview | N/A | |
| 2022-03-17 15:21 EST | News | MediWound Q4 2021 Earnings Preview | N/A | |
| 2022-03-17 15:20 EST | News | MediWound GAAP EPS of -$0.15 in-line, revenue of $5.49M misses by $0.05M | N/A | |
| 2022-03-17 15:19 EST | News | MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-03 14:30 EST | News | MediWound slumps on pricing $10M stock offering | N/A | |
| 2022-03-02 20:11 EST | News | MediWound slides on proposed stock offering | N/A | |
| 2022-02-10 11:47 EST | News | MediWound wins $9M additional BARDA funding for NexoBrid | N/A | |
| 2022-01-24 07:28 EST | News | MediWound reports positive results from Phase 2 trial of EscharEx for debridement of chronic wounds | N/A | |
| 2021-12-20 10:51 EST | News | MediWound reports positive initial data from Phase 2 EscharEx study in chronic, hard to heal wounds | N/A | |
| 2021-11-17 00:12 EST | News | MediWound EPS beats by $0.01, beats on revenue | N/A | |
| 2021-11-17 00:12 EST | News | MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-16 04:19 EST | News | MediWound Q3 2021 Earnings Preview | N/A | |
| 2021-10-13 04:34 EST | News | Warning: MDWD is at high risk of performing badly | N/A | |
| 2021-10-06 12:47 EST | News | MDWD is at high risk of performing badly | N/A | |
| 2021-09-27 21:29 EST | News | Warning: MDWD has been downgraded to Very Bearish | N/A | |
| 2021-09-22 00:18 EST | News | Warning: MDWD has been downgraded to Very Bearish. | N/A | |
| 2021-08-11 04:24 EST | News | Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-10 07:32 EST | News | MediWound EPS misses by $0.01, beats on revenue | N/A | |
| 2021-07-30 17:24 EST | News | MediWound: Disappointing Thus Far But Still A Strong Buy | N/A | |
| 2021-07-29 01:24 EST | News | MediWound: Adjusting My Strategy After NexoBrid CRL | N/A | |
| 2021-07-21 15:33 EST | News | MediWound completes enrollment for interim assessment of mid-stage EscharEx study | N/A | |
About MediWound Ltd (MDWD):
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
General
- Name MediWound Ltd
- Symbol MDWD
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 75
- Fiscal Year EndDecember
- IPO Date2014-03-20
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.mediwound.com
View More
Valuation
- Trailing PE 27.07
- Price/Sales (Trailing 12 Mt.) 7.03
- Price/Book (Most Recent Quarter) 21.05
- Enterprise Value Revenue 6.13
- Enterprise Value EBITDA 15.35
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.24
- Next Year EPS Estimate -$0.54
- Next Quarter EPS Estimate -$0.12
- Profit Margin -42%
- Operating Margin -40%
- Return on Assets -15%
- Return on Equity -83%
- Revenue 21.76 million
- Earnings Per Share $0.24
- Revenue Per Share $0.8
- Gross Profit 7.55 million
- Quarterly Earnings Growth 22.6%
View More
Highlights
- Market Capitalization 155.8 million
- EBITDA 8.18 million
- PE Ratio -9.93
- PEG Ratio -0.07
- Analyst Target Price $7.67
- Book Value Per Share $0.27
View More
Share Statistics
- Shares Outstanding 27.24 million
- Shares Float 16.8 million
- % Held by Insiders 4277%
- % Held by Institutions 18.85%
- Shares Short 33009
- Shares Short Prior Month 21560
- Short Ratio 0.22
View More
Technicals
- Beta 1.54
- 52 Week High $6.07
- 52 Week Low $1.44
- 50 Day Moving Average 5.41
- 200 Day Moving Average 4.22
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
MediWound Ltd (MDWD) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
MediWound Ltd (MDWD) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-25 | $N/A | -$0.06 | -$0.11 | 45.45% |
| 2020-09-30 | 2020-11-10 | $6.63 million | -$0.07 | -$0.10 | 27.08% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.11 | -$0.12 | 8.33% |
| 2020-03-31 | 2020-05-20 | $4.44 million | -$0.09 | -$0.14 | 36.84% |
| 2019-12-31 | 2020-02-25 | $5.44 million | -$0.13 | -$0.10 | -25% |
| 2019-09-30 | 2019-11-14 | $5.14 million | -$0.11 | -$0.13 | 15.38% |
| 2019-06-30 | 2019-08-12 | $20.75 million | $0.47 | -$0.03 | 1907.69% |
| 2019-03-31 | 2019-05-21 | $461000 | -$0.15 | -$0.14 | -7.14% |
| 2018-12-31 | 2019-03-25 | $992000 | $0.22 | -$0.15 | 244.74% |
| 2018-09-30 | 2018-11-13 | $858000 | -$0.11 | -$0.20 | 43.88% |
| 2018-06-30 | 2018-08-07 | $1.03 million | -$0.15 | -$0.20 | 23.47% |
| 2018-03-31 | 2018-05-10 | $520000 | -$0.17 | -$0.14 | -25.93% |
| 2017-12-31 | 2018-03-19 | $530000 | -$0.08 | -$0.18 | 54.93% |
| 2017-09-30 | 2017-11-16 | $739000 | -$0.16 | -$0.19 | 15.79% |
| 2017-06-30 | 2017-08-03 | $687000 | -$0.20 | -$0.20 | -2.04% |
| 2017-03-31 | 2017-05-08 | $540000 | -$0.20 | -$0.17 | -19.05% |
| 2016-12-31 | 2017-02-21 | $430000 | -$0.09 | -$0.25 | 63.71% |
| 2016-09-30 | 2016-11-14 | $518000 | -$0.26 | -$0.26 | -0.97% |
| 2016-06-30 | 2016-07-28 | $356000 | -$0.34 | -$0.24 | -42.68% |
| 2016-03-31 | 2016-04-21 | $254000 | -$0.17 | -$0.24 | 29.52% |
| 2015-12-31 | 2016-01-25 | $267000 | -$0.36 | -$0.23 | -54.51% |
| 2015-09-30 | 2015-10-27 | $102000 | -$0.17 | -$0.31 | 45.16% |
| 2015-06-30 | 2015-08-03 | $165000 | -$0.19 | -$0.26 | 26.92% |
| 2015-03-31 | 2015-05-04 | $67000 | -$0.30 | -$0.25 | -20% |
| 2014-12-31 | 2015-02-12 | $124000 | -$0.33 | -$0.26 | -26.92% |
| 2014-09-30 | 2014-11-05 | $46000 | -$0.24 | -$0.24 | 0% |
| 2014-06-30 | 2014-07-31 | $39000 | -$0.28 | -$0.17 | -64.71% |
| 2014-03-31 | 2014-05-02 | $50000 | -$0.05 | -$0.17 | 70.59% |
MediWound Ltd (MDWD) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
MediWound Ltd (MDWD) Chart:
MediWound Ltd (MDWD) News:
Below you will find a list of latest news for MediWound Ltd (MDWD) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
MediWound Ltd (MDWD) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-21 | 5 | 14.26 | CALL | 0 | 0 | 141.29 | TRUE | 0 | 0 |
| 2025-03-21 | 7.5 | 10.75 | CALL | 0 | 0 | 115.79 | TRUE | 0 | 0 |
| 2025-03-21 | 10 | 0 | CALL | 0 | 0 | 93.91 | TRUE | 0 | 0 |
| 2025-03-21 | 12.5 | 0 | CALL | 0 | 0 | 80.3 | TRUE | 0 | 0 |
| 2025-03-21 | 15 | 6.6 | CALL | 0 | 5 | 78.24 | TRUE | 0 | 0 |
| 2025-03-21 | 17.5 | 5.11 | CALL | 0 | 5 | 76.73 | FALSE | 0 | 0 |
| 2025-03-21 | 20 | 2.5 | CALL | 0 | 41 | 74.78 | FALSE | 0 | 0 |
| 2025-03-21 | 22.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 25 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 30 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 35 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 7.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 10 | 0.7 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 12.5 | 1.2 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2025-03-21 | 15 | 2.4 | PUT | 0 | 9 | 88.5 | FALSE | 0 | 0 |
| 2025-03-21 | 17.5 | 3.12 | PUT | 0 | 2 | 59.07 | TRUE | 0 | 0 |
| 2025-03-21 | 20 | 0 | PUT | 0 | 0 | 65.06 | TRUE | 0 | 0 |
| 2025-03-21 | 22.5 | 0 | PUT | 0 | 0 | 46.2 | TRUE | 0 | 0 |
| 2025-03-21 | 25 | 0 | PUT | 0 | 0 | 49.09 | TRUE | 0 | 0 |
| 2025-03-21 | 30 | 0 | PUT | 0 | 0 | 54.2 | TRUE | 0 | 0 |
| 2025-03-21 | 35 | 0 | PUT | 0 | 0 | 118.49 | TRUE | 0 | 0 |
Latest MDWD Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 2:52 PM EST | 200 | $1.74 |
MediWound Ltd (MDWD) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320001946/0001178913-20-001946-index.htm |
| 2019-04-08 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1593984/000000000019006753/0000000000-19-006753-index.htm |
| 2017-02-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000090221917000257/0000902219-17-000257-index.htm |
| 2017-08-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000090221917000560/0000902219-17-000560-index.htm |
| 2018-02-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000090221918000039/0000902219-18-000039-index.htm |
| 2019-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000090221919000059/0000902219-19-000059-index.htm |
| 2020-01-28 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000090221920000291/0000902219-20-000291-index.htm |
| 2020-06-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000090221920000393/0000902219-20-000393-index.htm |
| 2017-01-31 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000117891317000232/0001178913-17-000232-index.htm |
| 2017-01-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317000245/0001178913-17-000245-index.htm |
| 2017-02-01 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000117891317000255/0001178913-17-000255-index.htm |
| 2017-02-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317000291/0001178913-17-000291-index.htm |
| 2017-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000117891317000310/0001178913-17-000310-index.htm |
| 2017-02-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317000371/0001178913-17-000371-index.htm |
| 2017-02-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317000573/0001178913-17-000573-index.htm |
| 2017-02-21 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317000577/0001178913-17-000577-index.htm |
| 2017-05-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317001307/0001178913-17-001307-index.htm |
| 2017-05-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317001527/0001178913-17-001527-index.htm |
| 2017-05-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317001531/0001178913-17-001531-index.htm |
| 2017-06-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317001883/0001178913-17-001883-index.htm |
| 2017-07-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317002090/0001178913-17-002090-index.htm |
| 2017-08-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317002253/0001178913-17-002253-index.htm |
| 2017-09-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317002600/0001178913-17-002600-index.htm |
| 2017-09-05 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000117891317002608/0001178913-17-002608-index.htm |
| 2017-09-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317002630/0001178913-17-002630-index.htm |
| 2017-09-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317002691/0001178913-17-002691-index.htm |
| 2017-09-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317002695/0001178913-17-002695-index.htm |
| 2017-09-19 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317002697/0001178913-17-002697-index.htm |
| 2017-09-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317002703/0001178913-17-002703-index.htm |
| 2017-10-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317002869/0001178913-17-002869-index.htm |
| 2017-10-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317002900/0001178913-17-002900-index.htm |
| 2017-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317003131/0001178913-17-003131-index.htm |
| 2017-11-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891317003176/0001178913-17-003176-index.htm |
| 2018-01-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891318000170/0001178913-18-000170-index.htm |
| 2018-01-22 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000117891318000211/0001178913-18-000211-index.htm |
| 2018-01-31 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000117891318000314/0001178913-18-000314-index.htm |
| 2018-02-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000117891318000365/0001178913-18-000365-index.htm |
| 2018-02-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000117891318000428/0001178913-18-000428-index.htm |
| 2018-02-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891318000676/0001178913-18-000676-index.htm |
| 2018-03-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891318000885/0001178913-18-000885-index.htm |
| 2018-03-19 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1593984/000117891318000887/0001178913-18-000887-index.htm |
| 2018-03-19 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1593984/000117891318000892/0001178913-18-000892-index.htm |
| 2018-05-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891318001565/0001178913-18-001565-index.htm |
| 2018-05-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891318001584/0001178913-18-001584-index.htm |
| 2018-06-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891318001883/0001178913-18-001883-index.htm |
| 2018-06-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891318001923/0001178913-18-001923-index.htm |
| 2018-06-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891318001929/0001178913-18-001929-index.htm |
| 2018-08-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891318002304/0001178913-18-002304-index.htm |
| 2018-09-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891318002568/0001178913-18-002568-index.htm |
| 2018-11-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891318002903/0001178913-18-002903-index.htm |
| 2019-01-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319000121/0001178913-19-000121-index.htm |
| 2019-02-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000117891319000309/0001178913-19-000309-index.htm |
| 2019-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000117891319000381/0001178913-19-000381-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000117891319000454/0001178913-19-000454-index.htm |
| 2019-03-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319000792/0001178913-19-000792-index.htm |
| 2019-03-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319000909/0001178913-19-000909-index.htm |
| 2019-03-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319000911/0001178913-19-000911-index.htm |
| 2019-03-25 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319000913/0001178913-19-000913-index.htm |
| 2019-03-25 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1593984/000117891319000920/0001178913-19-000920-index.htm |
| 2019-03-25 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1593984/000117891319000922/0001178913-19-000922-index.htm |
| 2019-03-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319000924/0001178913-19-000924-index.htm |
| 2019-04-12 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1593984/000117891319001120/0001178913-19-001120-index.htm |
| 2019-04-18 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1593984/000117891319001183/0001178913-19-001183-index.htm |
| 2019-05-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319001289/0001178913-19-001289-index.htm |
| 2019-05-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319001363/0001178913-19-001363-index.htm |
| 2019-05-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319001559/0001178913-19-001559-index.htm |
| 2019-05-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319001605/0001178913-19-001605-index.htm |
| 2019-06-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319001690/0001178913-19-001690-index.htm |
| 2019-07-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319001934/0001178913-19-001934-index.htm |
| 2019-08-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319002149/0001178913-19-002149-index.htm |
| 2019-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319002192/0001178913-19-002192-index.htm |
| 2019-08-23 | 6-K/A | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319002251/0001178913-19-002251-index.htm |
| 2019-09-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319002438/0001178913-19-002438-index.htm |
| 2019-10-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319002449/0001178913-19-002449-index.htm |
| 2019-10-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319002453/0001178913-19-002453-index.htm |
| 2019-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319002734/0001178913-19-002734-index.htm |
| 2019-12-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891319002874/0001178913-19-002874-index.htm |
| 2020-01-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320000022/0001178913-20-000022-index.htm |
| 2020-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000117891320000279/0001178913-20-000279-index.htm |
| 2020-02-06 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000117891320000291/0001178913-20-000291-index.htm |
| 2020-02-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320000638/0001178913-20-000638-index.htm |
| 2020-02-25 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320000640/0001178913-20-000640-index.htm |
| 2020-02-25 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320000647/0001178913-20-000647-index.htm |
| 2020-02-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320000649/0001178913-20-000649-index.htm |
| 2020-02-25 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1593984/000117891320000651/0001178913-20-000651-index.htm |
| 2020-03-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320000684/0001178913-20-000684-index.htm |
| 2020-03-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320000956/0001178913-20-000956-index.htm |
| 2020-04-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320001215/0001178913-20-001215-index.htm |
| 2020-05-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320001535/0001178913-20-001535-index.htm |
| 2020-05-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320001551/0001178913-20-001551-index.htm |
| 2020-06-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320001896/0001178913-20-001896-index.htm |
| 2020-07-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320001946/0001178913-20-001946-index.htm |
| 2020-08-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320002286/0001178913-20-002286-index.htm |
| 2020-08-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320002493/0001178913-20-002493-index.htm |
| 2020-09-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320002640/0001178913-20-002640-index.htm |
| 2020-10-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320002913/0001178913-20-002913-index.htm |
| 2020-10-30 | 6-K/A | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1593984/000117891320002949/0001178913-20-002949-index.htm |
| 2017-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000119312517043820/0001193125-17-043820-index.htm |
| 2018-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000119312518045765/0001193125-18-045765-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000119312519039173/0001193125-19-039173-index.htm |
| 2019-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000121390019002073/0001213900-19-002073-index.htm |
| 2020-01-27 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1593984/000121390020001894/0001213900-20-001894-index.htm |
| 2019-04-22 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1593984/999999999519000785/9999999995-19-000785-index.htm |
| 2017-02-28 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1593984/999999999717001269/9999999997-17-001269-index.htm |
| 2017-03-20 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1593984/999999999717003766/9999999997-17-003766-index.htm |
| 2019-04-09 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1593984/999999999719002564/9999999997-19-002564-index.htm |